



Amgen USA Inc.
1 Amgen Center Drive
Thousand Oaks, CA 91320 USA
(805) 447-1000

amgen.com

MODIFIED January 12, 2026 TO REFLECT AN UPDATE TO AMGEN'S 340B CONTRACT PHARMACY POLICY

Dear Valued Customer,

I am writing to inform you that, effective January 1, 2026, Amgen Inc. (Amgen) is updating its 340B contract pharmacy policy..

HRSA's Office of Pharmacy Affairs (OPA) announced on December 31, 2025 that it is pausing the implementation of the 340B Rebate Model Pilot Program for all covered entity types at this time. Effective January 1, 2026, Amgen is suspending implementation of its HRSA-approved 340B Rebate Model Pilot Program. Amgen's Contract Pharmacy Policy will continue to apply as follows:

Enbrel®, Repatha®, Otezla®, Aimovig®, Tezspire®, and Amjevit®

Amgen's 340B Contract Pharmacy policy will apply, as described below, to all states other than the states listed in **Attachment A**. Effective December 23, 2025, covered entities in Oklahoma will no longer be exempt from Amgen's Contract Pharmacy policy. Designations made by covered entities in Oklahoma prior to December 23, 2025, will continue to apply. For covered entities that wish to update their designation can do so on the 340B ESP™ platform at www.340besp.com. Additionally, effective January 19, 2026, covered entities that do not have an in-house pharmacy capable of dispensing 340B-priced drugs to its patients and designate a single contract pharmacy location are also required to submit claims data for the designated single contract pharmacy to www.340besp.com.

Amgen's Contract Pharmacy policy:

Amgen will provide products purchased at the 340B price exclusively to locations registered as a 340B covered entity or other locations designated in accordance with Amgen's policy, as described below. Subject to the following exceptions, pharmacies registered as contract pharmacies will not be eligible for Bill To / Ship To orders:

Amgen's Contract Pharmacy policy is subject to the following exceptions:

Any covered entity may elect to designate any contract pharmacy location registered on the HRSA OPAIS database that is within 40 miles of the covered entity's parent site, or grantee site as listed in the HRSA database as its single contract pharmacy location and must submit claims data for the designated single contract pharmacy to www.340besp.com. If a covered entity with an in-house pharmacy elects to designate a single contract pharmacy, it must also submit claims data for the in-house pharmacy to www.340besp.com. Amgen will allow the use of a contract pharmacy



beyond the 40-mile radius where a covered entity shows that there is no contract pharmacy that is capable of purchasing and dispensing Amgen's drugs within a 40-mile radius of the covered entity's parent site, or grantee site as listed in the HRSA database if the covered entity submits claims data for the designated single contract pharmacy to www.340besp.com.

There is no action needed for covered entities that wish to retain their existing designation. For covered entities that wish to update their designation, they may do so on the 340B ESP™ platform at www.340besp.com.

Best regards,

A handwritten signature in black ink, appearing to read "David R. Zimmer". The signature is fluid and cursive, with "David" and "R." on the first line and "Zimmer" on the second line.

David Zimmer
Vice President, US Value & Access



Frequently Asked Questions

Q: Which products are subject to Amgen's 340B Contract Pharmacy Policy?

A: The current policy primarily applies to self-administered, pharmacy benefit Amgen products, specifically **Repatha®**, **Enbrel®**, **Otezla®**, **Aimovig®**, **Tezspire®** and **Amjevit®**.

Q: If a covered entity has a contract pharmacy relationship with a pharmacy that is wholly owned or under common ownership with the covered entity's health system, is this pharmacy subject to Amgen's policy?

A: Any covered entity may elect to designate any contract pharmacy location registered on the HRSA OPAIS database that is within 40 miles of the covered entity's parent site, or grantee site as listed in the HRSA database, regardless of ownership interest, as its single contract pharmacy location as long as it submits claims data for the designated single contract pharmacy to www.340besp.com. If a covered entity with an in-house pharmacy elects to designate a single contract pharmacy, it must also submit claims data for the in-house pharmacy to www.340besp.com. Amgen will allow the use of a contract pharmacy beyond the 40-mile radius where a covered entity shows that there is no contract pharmacy that is capable of purchasing and dispensing Amgen's drugs within a 40-mile radius of the covered entity's parent site, or grantee site as listed in the HRSA database if the covered entity submits claims data for the designated single contract pharmacy to www.340besp.com.

Q: If a covered entity has an in-house pharmacy that is capable of purchasing and dispensing Amgen drugs, but the entity doesn't currently use it to dispense Amgen drugs, can the entity designate one contract pharmacy instead?

A: Any covered entity may elect to designate any contract pharmacy location registered on the HRSA OPAIS database that is within 40 miles of the covered entity's parent site, or grantee site as listed in the HRSA database, as its single contract pharmacy location as long as it submits claims data for the designated single contract pharmacy to www.340besp.com. If a covered entity with an in-house pharmacy elects to designate a single contract pharmacy, it must also submit claims data for the in-house pharmacy to www.340besp.com. Amgen will allow the use of a contract pharmacy beyond the 40-mile radius where a covered entity shows that there is no contract pharmacy that is capable of purchasing and dispensing Amgen's drugs within a 40-mile radius of the covered entity's parent site, or grantee site as listed in the HRSA database if the covered entity submits claims data for the designated single contract pharmacy to www.340besp.com.



Q: What happens if a covered entity does not have an in-house pharmacy that is capable of purchasing and dispensing Amgen drugs and does not have a contract pharmacy within the 40-mile radius of the parent site, or grantee site as listed in the HRSA database?

A: Amgen will allow the use of a contract pharmacy beyond the 40-mile radius where a covered entity shows that there is no contract pharmacy that is capable of purchasing and dispensing Amgen's drugs within a 40-mile radius of the covered entity's parent site, or grantee site as listed in the HRSA database if the covered entity submits claims data for the designated single contract pharmacy to www.340besp.com.

Q: If a 340B covered entity has contract pharmacy arrangements with multiple locations of the same pharmacy, can the entity designate all locations of the same pharmacy?

A: Amgen's policy allows 340B covered entities to designate a single contract pharmacy location. Contract pharmacy locations are registered individually on the HRSA database and 340B covered entities are permitted to designate only a single contract pharmacy location which corresponds to a single contract pharmacy registration with HRSA OPAIS.

Q: How can a 340B covered entity change its contract pharmacy designation?

A: Covered entities may change their contract pharmacy designation once every twelve (12) months (from the date of first designation) or more often if the designated contract pharmacy relationship is terminated from the HRSA OPAIS database. Changes to the single contract pharmacy can only be made by visiting www.340besp.com/designations. Users that have registered an account with 340B ESP™ can navigate to the Entity Profile tab to make their contract pharmacy designation.

Q: Is Amgen requiring covered entities to have a HIN registered for the contract pharmacy that they designate?

A: Yes, a contract pharmacy must have a HIN assigned to it in order for a covered entity to designate it as its single contract pharmacy. This information is important for Amgen to manage its process with its wholesalers.

Q: If the contract pharmacy that a covered entity wants to designate doesn't have a HIN, how can one be obtained?

A: Amgen will not register a HIN on behalf of a covered entity. However, if a covered entity needs guidance or more information on how to get a HIN assigned to a contract pharmacy, please reach out to support@340besp.com. If a covered entity tries to designate a contract



pharmacy without a HIN in 340B ESP™, the system will notify the covered entity of this requirement and provide instructions for how to obtain a HIN.

Q: How many days does it take for a contract pharmacy designation made by a covered entity to take effect?

A: Please allow 10 business days for a covered entity's contract pharmacy designation to take effect.

Q: If a covered entity would like to submit 340B claims for its in-house pharmacy and contract pharmacy and continue purchasing Amgen products at the 340B price, what does the entity need to do to begin submitting claims data?

A: 340B covered entities that wish to submit claims data under Amgen's policy can do so by registering an account at www.340besp.com. Users that have registered an account with 340B ESP™ can begin submitting claims for Amgen by navigating to the Claims Data Submission tab.

Q: What happens if a covered entity does not provide 340B contract pharmacy claims data by the required date?

A: If a covered entity elects not to submit claims data for its contract pharmacy, the covered entity can continue receiving 340B-priced products at the covered entity's in-house pharmacy. If the covered entity does not have an in-house pharmacy capable of dispensing products purchased at the 340B price, the covered entity may designate a single contract pharmacy in accordance with Amgen's policy.



Attachment A

Arkansas: Effective April 2, 2024, contract pharmacy arrangements between 340B covered entities located in Arkansas and contract pharmacies located in Arkansas are exempt from Amgen's 340B contract pharmacy policy.

Maryland: Effective July 1, 2024, contract pharmacy arrangements between 340B covered entities located in Maryland and contract pharmacies located in Maryland are exempt from Amgen's 340B contract pharmacy policy.

Mississippi: Effective July 1, 2024, contract pharmacy arrangements between 340B covered entities located in Mississippi and contract pharmacies located in Mississippi are exempt from Amgen's 340B contract pharmacy policy.

Missouri: Effective August 28, 2024, contract pharmacy arrangements between 340B covered entities located in Missouri and contract pharmacies located in Missouri are exempt from Amgen's 340B contract pharmacy policy.

Utah: Effective May 7, 2025, contract pharmacy arrangements between 340B covered entities located in Utah and contract pharmacies located in Utah are exempt from Amgen's 340B contract pharmacy policy.

South Dakota: Effective July 1, 2025, contract pharmacy arrangements between 340B covered entities located in South Dakota and contract pharmacies located in South Dakota are exempt from Amgen's 340B contract pharmacy policy.

North Dakota: Effective August 1, 2025, contract pharmacy arrangements between 340B covered entities located in North Dakota and contract pharmacies located in North Dakota are exempt from Amgen's 340B contract pharmacy policy.

Tennessee: Effective June 2, 2025, contract pharmacy arrangements between 340B covered entities located in Tennessee and contract pharmacies located in Tennessee are exempt from Amgen's 340B contract pharmacy policy.

Vermont: Effective June 1, 2025, contract pharmacy arrangements between 340B covered entities located in Vermont and contract pharmacies located in Vermont are exempt from Amgen's 340B contract pharmacy policy.



Hawaii: Effective July 1, 2025, contract pharmacy arrangements between 340B covered entities located in Hawaii and contract pharmacies located in Hawaii are exempt from Amgen's 340B contract pharmacy policy.

Nebraska: Effective April 9, 2025, contract pharmacy arrangements between 340B covered entities located in Nebraska and contract pharmacies located in Nebraska are exempt from Amgen's 340B contract pharmacy policy.

New Mexico: Effective January 1, 2026, contract pharmacy arrangements between 340B covered entities located in New Mexico and contract pharmacies located in New Mexico are exempt from Amgen's 340B contract pharmacy policy.